



BSW Formulary Updates and Recent Decisions – July/August 2024*

New additions to BSW formulary and Change in Traffic Light status

- [Adacel 0.5ml suspension for injection in PFS](#) added with **GREEN TLS**. ADACEL® replaces Boostrix-IPV® for the national pertussis vaccination in pregnancy programme. Read more [here](#)
- [Abrysvo® powder and solvent for solution for injection](#) added with **GREEN TLS**. Approved for use for the adult national RSV programme. Read more [here](#)
- [Lanthanum](#) chewable tablets and [sevelamer](#) tablets and oral powder aligned as **AMBER TLS**. For initiation by renal team only but ongoing prescribing in primary care is permitted.
- [SMA Soya infant formula](#). Added with **AMBER TLS** for galactosaemia patients only. There is a national shortage of SMA Soya Infant Formula which is the only available soya based infant formula in the UK. To protect this resource for galactosaemia patients, SMA Soya Infant Formula is currently only available on prescription and Nestle are operating a prescription validation service for it to try to protect supplies. Nestle recommend that no new patients should be started on SMA Soya Infant Formula.

Minor amendments to BSW formulary

- BMS & NHSE summary guidance on [Management of Unscheduled Bleeding on Hormone Replacement Therapy](#) added to top of section [06.04.01.01](#)
- SPS guidance on [Prescribing and ordering available pancreatic enzyme replacement therapies](#) added to entries in section [01.09.04](#)
- FSRH statement: [Extended use of all 52mg LNG-IUDs for up to eight years for contraception](#) added to top of section [07.03.02.03](#)
- SPS article on [Issues affecting Pabrinex - Using and prescribing thiamine in alcohol dependence](#) added to entries in section [09.06.02](#)
- Exenatide immediate release injection (Byetta®); topical capsaicin; and tinidazole tablets removed from formulary; either experiencing long term unavailability or discontinued.
- Information on preferred brands included in [melatonin \(adult\)](#) entry. Liquid formulation is a second line option only after crushed Adaflex® has been tried and is unsuitable. On FP10, it should be prescribed as Ceyesto® 1 mg/ml oral solution. Acute trusts use melatonin 1mg/ml oral solution (Colonis) in line with contract.
- 250mg strength tablet added to [mefenamic acid](#) entry
- Information added on use of [loperamide in high output stoma or short bowel syndrome](#)
- [Hydrogen peroxide 1.5% mouthwash](#) reinstated as formulary option now its freely available. **RED TLS** for post-surgical indications; for other indications, should be self-purchase.



- Viscotears brand of carbomer 0.2% eye gel UDVs included in [paediatric chapter](#) as preferred brand of lubricant for conducting retinopathy of prematurity screening/imaging. **RED TLS**. For preferred products/brands in the management of dry eye, continue to refer to [BSW Prescribing Guidelines for Dry Eye](#)

New entries and links added in line with publication of NICE TAs. **RED TLS**

- [TA971 Remdesivir for treating COVID-19](#)
- [TA973 Atogepant for preventing migraine](#)

What the BSW ICB formulary team are currently working on

- Working with colleagues in Public Health to review the Immunological products and vaccines chapter [Formulary \(bswformulary.nhs.uk\)](#)
- Working with colleagues across BSW to review the Palliative care chapter [Formulary \(bswformulary.nhs.uk\)](#)
- Working with BSW respiratory colleagues to produce asthma guidance for Children and Young People

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net

*No meeting in August 2024; decisions ratified by email.